Today, the House and Senate released the new bipartisan, bicameral agreement on the Synthetics Trafficking and Overdose Prevention (STOP) Act, legislation to help prevent the shipment of synthetic opioids into the United States through the international mail system.

The Department of Justice (DOJ) announced last night it will not defend several critical patient protections in the health law and instead is arguing to end them.

Penn Medicine researchers are calling for greater precision in Medicare performance reporting for patients with gastrointestinal (GI) bleeding following an evaluation of patients with the condition.

The American Cancer Society Cancer Action Network (ACS CAN), Friends of Cancer Research (FOCR), and the National Organization for Rare Disorders (NORD) along with more than 100 advocacy groups representing millions of patients submitted a letter to Members of the House of Representatives strongly opposing the Senate Right-to-Try Act (S. 204).

Starting Wednesday, a new law will protect New Mexico’s cancer patients from health risks caused by step therapy — also known as “fail first” therapy.

Today, the American Hospital Association (AHA) commended the introduction of the Rural Emergency Medical Center (REMC) Act of 2018 (H.R. 5678) by Representatives Lynn Jenkins (R-KS), Ron Kind (D-WI) and Terri Sewell (D-AL).

The Biotechnology Innovation Organization (BIO) and BioForward Wisconsin commend Governor Scott Walker for signing critical legislation to create a pathway for the substitution of interchangeable biologic medicines, with appropriate communication to patients and physicians.

The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, this time for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.

Merck said Lynparza (olaparib), a targeted therapy co-developed with AstraZeneca, has become the first PARP inhibitor approved by the Food and Drug Administration for treating metastatic breast cancer.

In a collaboratively funded government effort advancing treatments for the Zika virus, scientists recently announced that an exploratory version of the Zika purified inactivated virus (ZPIV) proved safe, tolerated and effective in national study participants.

GlaxoSmithKline plc recently received Food and Drug Administration (FDA) approval for Nucala (mepolizumab) to target a form of vasculitis called eosinophilic granulomatosis with polyangiitis (EGPA).

Eli Lilly and Co. recently embarked on a feasibility study to assess its Connected Diabetes Ecosystem’s automated insulin delivery (AID) treatment for patients with Type 1 diabetes.

Amgen recently attained approval from the Food and Drug Administration (FDA) for Repatha following a priority review of the company’s supplemental biologics license application.

The National Institutes of Health (NIH) recently launched a clinical trial for an experimental vaccine that aims prevent HIV infection.

While multibillion-dollar mega-mergers at the top of the end of the health-sector chain garner headlines and potential regulatory scrutiny, hospital group consolidations are also concerning experts who believe they may not produce better care and lower costs.

Details of a $69 billion deal in which pharmacy giant CVS would take over health insurer Aetna emerged in multiple reports Sunday.

Novartis has had received positive topline results from its global MONALEESA-7 trial of Kisqali for metastatic breast cancer, the company announced in a press release.

EMD Serono, Merck KGaA’s U.S. and Canada-based biopharmaceutical business, recently received Food and Drug Administration approval for a redesigned version of a pen injector, designed to be used to induce ovulation and pregnancy in certain oligo-anovulatory women.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion of AstraZeneca's and MedImmune's benralizumab, which is designed to treat adults with severe eosinophilic asthma.

Abbott has received approval from Japan’s Ministry of Health, Labor and Welfare for the company’s MitraClip, making it the first minimally invasive device to treat people in Japan with mitral regurgitation (MR) heart disease.